Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wow now that's some powerful information from a polished AMBS CEO. Multiple multi billion dollar target markets, exciting data and important orphan info coming in the 3rd quarter for this once in a lifetime investment. Significant revenues for AMBS is right around the corner.
MANF your thoughts on future AMBS events will come true. Your ability to predict the future is certain
and amazing.
One day those whose fear to invest now in this life healing company at this PPS will shake their heads knowing that it was all right in front of them... all they had to do was believe.
Magical events soon to be revealed... it is all being created right now. AMBS is a lock. Love investing in this company.
Nothing Magical Here What a lock.AMBS
Another green AMBS day and this is only the beginning of the magical 50 x run from this PPS. This AMBS run is a copy cat of the first monster run when I first got on board... Except this one is going significantly higher due to multiple funding sources and related publicity. This Is fun. AMBS
How do you conclude that an evaluation, a proof-of-concept clinical study, that begins at an unspecified date in the 2nd half of 2013 could be finished within as little as 30-60 days?
BH, how do you conclude it could not? Who here knows when the specified date began. Why the pessimism?
AMBS has more going on than than any single person could ever guesstimate. The boat is ready to sail. AMBS.
Big news is just ahead with AMBS and the NFL connection... and another big time investment with unlimited funds will send AMBS to orbit. Been buying this fantastic conpany for almost a year with a smile on my face knowing I got a 100 bagger. The big run is started again and X 10...get ready for blastoff. AMBS is your once in a lifetime investment. Enjoy the ride.
Me, my friends, my family, and those I invite buy AMBS every week. Sorry to push aside the deep thinkers as these 100 times .04 returns pass u by. Cash Back Kaboom! AMBS
I been to Key West and it ain't no location for verification of any kind. Love AMBS
Buying back in tomorrow...love AMBS.
Maybe a lot of smart people in medicine have not been invited. The chosen winner is known to a select few and will be announced soon. AMBS.
I'm following Jason's insight and picking up a bunch more of these undervalued AMBS shares tomorrow. Picked up 500k shares on last weeks positive ( and potentially long term) engagement with BD and appreciate the opportunity to load more to my long term AMBS investment strategy before blast off.
Glad to jump in with 500K plus AMBS shares today at bargain pricing. Holding all my shares for long term gains. Love AMBS. Today's news is a significant achievement for the AMBS CEO and the AMBS team.
CEO is doing a great job.
Love this investment. I think AMB" and BMSN are the two best investments in penny land. Big time holds that are going to reap fantastic rewards.
This NO-BS Company Delivers Time After Time.
High Quality AMBS Leadership on a mission to heal.
Just a question of who invest in the company, when and how many hundreds of millions they recieve.
Really looking forward to the next Seeking Alpha article.
AMBS is a once in a lifetime investment.
God what an investment. Big money will pour in...any moment.
I ain't complaining about today's discount shopping.
Love AMBS.
Great day today for all the smart AMBS investors. We sure are been lucky enough to load up on these buying dips these past few weeks. AMBS will rocket when the Swiss DD is in. Guaranteed.
Just picked up another 40k shares of AMBS. I love this investment!
Make believe poster...what does that mean?
This superstar company is going to make anyone sitting on the sidelines pray for a small fill when the inevitable PR arrives with the blockbuster news.
Once they blow the whistle to start the second half no longs are going to sell.
Placed multiple 50k plus orders all day today just a bit below the bid. They never let me in.
No longs are selling.
Today was a game between three players...the M's and investors looking to cash beer money for St Pat's day.
Any substantial bid I placed today below the ask was completely ignored...not even posted on the 2.
No longs are selling.
All they do is bring it down and fill a few thousand shares to shake the sheeple.
They know what they got.
The float is locked. AMBS is going to blast off at any moment.
MORE NEWS! Why These 4 Biotechs Could Be Next In Line To See Their Share Prices Rise
Mar 8 2013, 08:09 | 8 comments | includes: AMBS.OB, CHTP, MACK, PPHM
Why These 4 Biotechs Could Be Next In Line To See Their Share Prices Rise
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)
Biotech stocks have been some of the best performing stocks on Wall Street over the past 5 years and those trends have continued over the past year and in 2013. The Nasdaq Biotech ETF (IBB) is up 32% over the past year while the NYSE Arca Biotech ETF (FBT) has put in a move of close to 37%. Compare that to the S&P 500's measly returns of 15% and it is easy to see why Mr. Market gets excited about biotech stocks.
(click to enlarge)
Investors aren't the only ones putting money to work in biotech. Others joining in on the biotech action include large biotech companies looking to expand their molecule holdings and investment assets. In fact, on February 6, Elan (ELN) announced a multi-billion transaction with Biogen Idec (BIIB) where Elan sold its share of Tysabri to Biogen for an upfront payment of $3.25 billion plus royalties. The part that has the market excited is the fact that Elan said that a portion of the $3.25 billion will be invested into a variety of business assets. From a portfolio point of view, these assets will, characteristically, diversify Elan from a product, science/clinical, therapeutic, and geographic point of view. In other words, Elan is looking to make acquisitions, amongst other opportunities. Further, Elan has already spoken to several companies about potential deals, Chief Executive Kelly Martin told Reuters. "You can do a lot of things with $3 billion, you can buy companies, molecules, you can partner, you can share risk..." Martin said.
In another transaction in the space, Sanofi (SNY) said that it plans to buy more stock of Regeneron (REGN) and as a consequence, some analysts began speculating that this could be a precursor to Sanofi acquiring the whole company. Without further ado, here are four biotechs that may begin to see more interest in their shares due to the aftermentioned reasons:
Chelsea Therapeutics (CHTP) is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases, including central nervous system disorders. Chelsea is currently pursuing FDA approval in the U.S. for Northera (droxidopa), a novel, late-stage, orally-active therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure.
Just last month, CHTP's announcement of an update from the FDA sent its shares up 150%. Even with the jump in the stock's price, it has more room to run as analysts peg the stock's target at $4.50 vs. a current share price of $1.77.
In the release, the company announced that it received written guidance from the Director of the Office of New Drugs at the FDA stating that Study 306B has the potential to serve as the basis for a resubmission of a Northera (droxidopa) New Drug Application (NDA) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). The release also contained information on important dates for the company coming up in the balance of 2013 that may serve as catalysts for the shares. First, the company plans to file a resubmission of the Northera NDA in the late second quarter. If accepted, the company's application will be subject to a 6-month review period, which means a decision on the application will most likely come at the end of the year.
AMARANTUS BIOSCIENCEAMBS.OB) is an interesting name whose story has been generating a buzz in 2013. The company's main product in development is MANF, a highly potent, neurotrophic factor currently in pre-clinical development for the treatment of several apoptosis-related disorders. It is one of the four main protein therapies currently in testing for Parkinson's along with GDNF, Neurturin, and NGF. MANF's discovery protocols, utilizing their proprietary PhenoGuard Protein Discovery Engine, were designed to identify a molecule that would be highly selective for dopamine producing neurons of the Substantia Nigra.
Amarantus' chances with MANF just received a boost after Phytopharm, a UK company, failed in its attempt to develop a successful treatment for Parkinson's. Phytopharm's strategy for Parkinson's was a small molecule used in an attempt to reinvigorate the dead cells and raise the protein levels. To that effect, it obviously didn't succeed but it did narrow down the options available for Parkinson's. The other two methods currently in development to cure Parkinson's are gene and protein therapy, as mentioned above. Amarantus owns rights for both. A gene therapy for Parkinson's is currently in development by Ceregene, a private company, and results from the company's Phase 2b study for Parkinson's are expected in early 2013. Looking forward, that data should help provide some clarity in the gene versus protein therapy battle and serve as a catalyst for Amarantus shares once results come out and headlines start swirling.
The market size for Parkinson's disease is estimated to be $5 billion a year. Taking that fact into consideration in combination with MANF's potential in Parkinson's disease, makes the stock attractive. MANF and the other neurotrophic factors have several advantages over what is currently available on the market. They help regenerate cells, protect current cells, and prevent further worsening of the Parkinson's condition. The current treatments for Parkinson's just cover up the symptoms. In addition to the fact that you can only do that for so long before the underlying cells continue to fail, they also lead to side effects as it is nearly impossible to provide the right dosage required.
Amarantus is a micro-cap stock and many micro-cap stocks tend to be new and have no proven track record. Some of these companies have no assets or operations. Others have products and services that are still in development or have yet to be tested in the market.
Peregrine Pharma (PPHM) is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead product candidate bavituximab and novel brain cancer agent Cotara. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, which provides development and biomanufacturing services for both Peregrine and outside customers
After reaching $2.40 a share in early January, PPHM has dropped back down to the $1.30 range where it was at the turn of the new year. The catalyst for the drop has been PPHM's announcement of disappointing results from its Phase II trial for bavituximab for pancreatic cancer. Despite the drop, analysts are optimistic on the shares, slapping a target of $4.50 on the shares. Comparing that to its current price of $1.40, the shares look attractive.
Elan and others looking for M&A opportunities may pay particular attention to PPHM as the company has been mentioned as a takeover target. Also, the investment community's mood continues to be positive on the Peregrine story as the company is scheduled to present at three investor conferences in March.
Merrimack Pharmaceuticals (MACK) is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.
There is a lot of interest in Merrimack's lead drug candidate, MM-398 for pancreatic cancer, that may soon begin translating into a higher stock price. That is because if MM-398 for pancreatic cancer is successful, it could mean a big windfall for the company. The current available options for pancreatic cancer are limited in effectiveness and the market size is large. In fact, according to Transparency Market Research, the global pancreatic cancer drug market is projected to reach $1.2 billion by 2015. Analysts seem to agree with their $12 target on the stock that is currently at $6.50.
Here are the latest details on MM-398 for pancreatic cancer: The company has initiated a pivotal Phase 3 clinical trial of MM-398 for the treatment of patients with metastatic pancreatic cancer who have previously failed treatment with gemcitabine. The trial, called NAPOLI-1 (NAnoliPOsomaL Irinotecan), is a global, randomized, open label Phase 3 study. NAPOLI-1 calls for a total enrollment of 405 patients equally randomized across the three arms: MM-398 as a monotherapy and MM-398 in combination with 5-FU/LV compared with the shared control arm of 5-FU/LV. The FDA has granted MM-398 the orphan drug designation for the treatment of pancreatic cancer.
Another new review from Seeking Alpha. Love this great investment.
Such a joy....AMBS.
Great info my friend - thanks for the continued DD.
Like our LONG time friend(?) Solantey says...the word is spreading fast...investors will be visiting us from around the scientific and investment world.
Day and night. Every time zone.
Post the positive
Do it a few times a day.
Never gonna know when they will be knocking @ the IHUB door.
Squash the dreamless.
Let them know all the greatness that this superstar company has accomplished.
AMBS is a once in a lifetime investment.
By the way Solantey thanks for posting the links.
You are very welcome my fellow AMBS investor.
I would like to see every positive PR posted every day. Bold the highlights to inform those who are here to learn about the AMBS mission. Swamp the dreamless messengers.
This company has so many past accomplishments that they need to be updated daily for the neophytes to examine.
Understand... this board is not about you or me or the blackhawk....we have been here for a LONG time. Got three million plus.
Maybe the blackhawk tries to get some cheap ones by posting against those who get excited about the potential AMBS offers.
I just do not trust anyone who turns thier back on the positive messengers yet ignores the constant Ignorance on the other side.
AMBS is not about today.
AMBS is built on a foundation based on non-hyped PR's. Just the facts.
AMBS is built on its unique history.
It is the past history of this company that makes it the superstar investment that it is about to become.
Post on positive messengers. Repeat it every day. More people are reading your positive post than you can ever imagine.
I love and appreciate your efforts to spread the great news. Repeat it over and over again. This company's history sure is a lot to digest in one sitting. Bring it on.
And I know I am not alone in my gratitude.
Exactly. Sorry blackhawk...it is a positive message from our past. Learn to embrace them all.
One perfect piece of a positive message from the past fitting side by side to find cure for those in need.
AMBS is the ultimate investment.
More good news just out!
AMBS...they just keep working!
Every action AMBS completes is done to consummate a huge deal with big Pharma.
Yes it does. AMBS will have a new friend with big bucks at any moment.
Let it go.
Who needs that on our team...not I.
Your post is spot on. Our AMBS team works for minimum wage. They plod forward on a deep rooted concern to help find a cure for people in need. Obviously the money means nothing at this time.
They are consumed in a passionate way with something they love.
Picture them as a Monet, a Renoir, a starving artist with nothing but a passion to create what has not been created. True entrepreneurs. From nothing to AMBS billions.
This is a once in a lifetime investment.
The AMBS connection with Banyan is indeed hot.
Big news is coming our way any day.
AMBS is a great investment.
Good to have you as part of the AMBS team Solantey.
100 percent on the money gipper. Great Post.
The AMPS law firm is a main cog in the AMBS success wheel. True pros who deserve every share they were paid.
Love this penny that files all the necessary legal docs in a timely fashion.
AMBS is a great investment.
Thank for the update. Keep bringing us the positive AMBS news.
Beeker may soon be saying this is the only dollar I own.
Nice to see AMBS moving up with no news!
Just imagine when the big PR's POP!
This is only the beginning of a magic run that we will last for years.